Cargando…

Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy

Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Quenot, Jean-Pierre, Luyt, Charles-Edouard, Roche, Nicolas, Chalumeau, Martin, Charles, Pierre-Emmanuel, Claessens, Yann-Eric, Lasocki, Sigismond, Bedos, Jean-Pierre, Péan, Yves, Philippart, François, Ruiz, Stéphanie, Gras-Leguen, Christele, Dupuy, Anne-Marie, Pugin, Jérôme, Stahl, Jean-Paul, Misset, Benoit, Gauzit, Rémy, Brun-Buisson, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716933/
https://www.ncbi.nlm.nih.gov/pubmed/23830525
http://dx.doi.org/10.1186/2110-5820-3-21
_version_ 1782277621971681280
author Quenot, Jean-Pierre
Luyt, Charles-Edouard
Roche, Nicolas
Chalumeau, Martin
Charles, Pierre-Emmanuel
Claessens, Yann-Eric
Lasocki, Sigismond
Bedos, Jean-Pierre
Péan, Yves
Philippart, François
Ruiz, Stéphanie
Gras-Leguen, Christele
Dupuy, Anne-Marie
Pugin, Jérôme
Stahl, Jean-Paul
Misset, Benoit
Gauzit, Rémy
Brun-Buisson, Christian
author_facet Quenot, Jean-Pierre
Luyt, Charles-Edouard
Roche, Nicolas
Chalumeau, Martin
Charles, Pierre-Emmanuel
Claessens, Yann-Eric
Lasocki, Sigismond
Bedos, Jean-Pierre
Péan, Yves
Philippart, François
Ruiz, Stéphanie
Gras-Leguen, Christele
Dupuy, Anne-Marie
Pugin, Jérôme
Stahl, Jean-Paul
Misset, Benoit
Gauzit, Rémy
Brun-Buisson, Christian
author_sort Quenot, Jean-Pierre
collection PubMed
description Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and demonstration of infected material. We suggest that PCT be measured to help predict infection; however, available data are insufficient to decide on initiating antibiotics based on PCT levels. In adult patients suspected of community-acquired LRTI, we suggest withholding antibiotic therapy when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI, data are insufficient to recommend initiating therapy based on a single PCT level or even repeated measurements. For children with suspected bacterial meningitis, we recommend using a decision rule as an aid to therapeutic decisions, such as the Bacterial Meningitis Score or the Meningitest®; a single PCT level ≥0.5 ng/mL also may be used, but false-negatives may occur. In adults with suspected bacterial meningitis, we suggest integrating serum PCT measurements in a clinical decision rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL threshold. For ICU patients suspected of community-acquired infection, we do not recommend using a threshold serum PCT value to help the decision to initiate antibiotic therapy; data are insufficient to recommend using PCT serum kinetics for the decision to initiate antibiotic therapy in patients suspected of ICU-acquired infection. In children, CRP can probably be used to help discontinue therapy, although the evidence is limited. In adults, antibiotic discontinuation can be based on an algorithm using repeated PCT measurements. In non-immunocompromised out- or in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is < 0.25 ng/mL or has decreased by >80-90%, whether or not microbiological documentation has been obtained. For ICU patients who have nonbacteremic sepsis from a known site of infection, antibiotics can be stopped if the PCT level at day 3 is < 0.5 ng/mL or has decreased by >80% relative to the highest level recorded, irrespective of the severity of the infectious episode; in bacteremic patients, a minimal duration of therapy of 5 days is recommended.
format Online
Article
Text
id pubmed-3716933
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-37169332013-07-22 Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy Quenot, Jean-Pierre Luyt, Charles-Edouard Roche, Nicolas Chalumeau, Martin Charles, Pierre-Emmanuel Claessens, Yann-Eric Lasocki, Sigismond Bedos, Jean-Pierre Péan, Yves Philippart, François Ruiz, Stéphanie Gras-Leguen, Christele Dupuy, Anne-Marie Pugin, Jérôme Stahl, Jean-Paul Misset, Benoit Gauzit, Rémy Brun-Buisson, Christian Ann Intensive Care Review Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and demonstration of infected material. We suggest that PCT be measured to help predict infection; however, available data are insufficient to decide on initiating antibiotics based on PCT levels. In adult patients suspected of community-acquired LRTI, we suggest withholding antibiotic therapy when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI, data are insufficient to recommend initiating therapy based on a single PCT level or even repeated measurements. For children with suspected bacterial meningitis, we recommend using a decision rule as an aid to therapeutic decisions, such as the Bacterial Meningitis Score or the Meningitest®; a single PCT level ≥0.5 ng/mL also may be used, but false-negatives may occur. In adults with suspected bacterial meningitis, we suggest integrating serum PCT measurements in a clinical decision rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL threshold. For ICU patients suspected of community-acquired infection, we do not recommend using a threshold serum PCT value to help the decision to initiate antibiotic therapy; data are insufficient to recommend using PCT serum kinetics for the decision to initiate antibiotic therapy in patients suspected of ICU-acquired infection. In children, CRP can probably be used to help discontinue therapy, although the evidence is limited. In adults, antibiotic discontinuation can be based on an algorithm using repeated PCT measurements. In non-immunocompromised out- or in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is < 0.25 ng/mL or has decreased by >80-90%, whether or not microbiological documentation has been obtained. For ICU patients who have nonbacteremic sepsis from a known site of infection, antibiotics can be stopped if the PCT level at day 3 is < 0.5 ng/mL or has decreased by >80% relative to the highest level recorded, irrespective of the severity of the infectious episode; in bacteremic patients, a minimal duration of therapy of 5 days is recommended. Springer 2013-07-08 /pmc/articles/PMC3716933/ /pubmed/23830525 http://dx.doi.org/10.1186/2110-5820-3-21 Text en Copyright ©2013 Quenot et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Quenot, Jean-Pierre
Luyt, Charles-Edouard
Roche, Nicolas
Chalumeau, Martin
Charles, Pierre-Emmanuel
Claessens, Yann-Eric
Lasocki, Sigismond
Bedos, Jean-Pierre
Péan, Yves
Philippart, François
Ruiz, Stéphanie
Gras-Leguen, Christele
Dupuy, Anne-Marie
Pugin, Jérôme
Stahl, Jean-Paul
Misset, Benoit
Gauzit, Rémy
Brun-Buisson, Christian
Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
title Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
title_full Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
title_fullStr Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
title_full_unstemmed Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
title_short Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
title_sort role of biomarkers in the management of antibiotic therapy: an expert panel review ii: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716933/
https://www.ncbi.nlm.nih.gov/pubmed/23830525
http://dx.doi.org/10.1186/2110-5820-3-21
work_keys_str_mv AT quenotjeanpierre roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT luytcharlesedouard roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT rochenicolas roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT chalumeaumartin roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT charlespierreemmanuel roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT claessensyanneric roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT lasockisigismond roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT bedosjeanpierre roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT peanyves roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT philippartfrancois roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT ruizstephanie roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT grasleguenchristele roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT dupuyannemarie roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT puginjerome roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT stahljeanpaul roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT missetbenoit roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT gauzitremy roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy
AT brunbuissonchristian roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy